Here’s what you should know:
1. The drug companies are alleging Sandoz infringed on up to 28 claims concerning Linzess’ “patent 371.”
2. The companies filed the suit in a U.S. District Court in Delaware, following Sandoz’s recent amendment to its new drug application calling the alleged infringements invalid and unenforceable.
3. Allergan, Forest and Ironwood are seeking to delay the production and sale of Sandoz’s generic until at least 2033, when the patent will expire. The companies also want monetary relief.
4. This is not the first time Allergan, Forest and Ironwood have attempted to stop generic production of Linzess. In 2016, the companies sued several pharmaceutical manufacturers, Sandoz included, for infringing on up to 70 claims concerning nine of the drug’s patents.
5. The case is currently pending.
More articles on gastroenterology:
Healthcare-related lobbying hits $555M in 2017 — 6 statistics on lobbying in healthcare
Advanced Medical Group joins National Spine & Pain Centers — 4 things to know
Preoperative opioid users more likely to abuse opioids after TKA — 3 study insights
